NCT06104839Phase 2Recruiting
Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata
In the register
The register attaches this trial to NXC736 (NEXTGEN Bioscience), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 2
- Sponsor
- NEXTGEN Bioscience
- Participants (registry)
- 73
- Start
- September 2024
- Primary completion
- October 2026 (planned)
- Study completion
- January 2027 (planned)
- Last registry update
- April 2026
- Countries
- South Korea
Conditions studied: Alopecia Areata
Interventions: NXC736, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.